Warren writes FTC over concerns of two pharma deals, Reuters reports

Senator Elizabeth Warren wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals: Amgen’s (AMGN) planned acquisition of Horizon Therapeutics (HZNP) and Indivior’s (INVVY) plan to buy Opiant Pharmaceuticals (OPNT), Reuters reports. "Given these companies’ records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," Warren wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, according to Reuters. Reference Link